37.24 USD
↘ 1.72 (4.41%)AT CLOSE (11:59 AM EDT)
Kodiak Sciences Inc Common Stock
KODNASDAQ • USD
37.25
↗ 0.01 (0.01%)
POST MARKET (AS OF 06:07 PM EDT)
Post Market
AS OF 06:07 PM EDT
37.25
↗ 0.01 (0.01%)
Market: CLOSED
Kodiak Sciences Inc Common Stock (KOD) is currently trading at $37.27. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 1, 2026.
Open?$38.50
High?$38.75
Low?$36.36
Prev. Close?$38.96
Volume?742.5K
Avg. Volume?818.2K
VWAP?$37.44
Rel. Volume?0.91x
Bid / Ask
Bid?$27.17 × 100
Ask?$45.60 × 100
Spread?$18.43
Midpoint?$36.39
Valuation & Ratios
Market Cap?2.4B
Shares Out?62.6M
Float?31.2M
Float %?49.9%
P/E Ratio?N/A
P/B Ratio?21.75
EPS?-$3.69
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Employees
124
Market Cap
2.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-04
Address
1250 PAGE MILL RD
PALO ALTO, CA 94304
Phone: 650-281-0850
PALO ALTO, CA 94304
Phone: 650-281-0850
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?30
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.90Distress
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?33.56%Squeeze Risk
Short Interest?10.5M
Days to Cover?13.7
Free Float31.2M
Avg Daily Volume767.7K
Settlement Date2026-06-15
Financial Health
Current Ratio?3.54Strong
Quick Ratio?3.54Strong
Cash Ratio?3.42Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?21.75HIGH▾
Peers100
S&P6
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-10.4CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-205.8%WEAK▾
S&P3
ROA?-75.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-148118000
Enterprise Value?$2.3B
Fundamentals ratios updated end of day